Literature DB >> 11301107

Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia.

P Ferrao1, P Sincock, S Cole, L Ashman.   

Abstract

Drug compartmentalization as well as drug efflux can contribute to drug resistance. We demonstrate the presence of P-gp in intracellular vesicles in certain AML cell lines and show localization of DNR to a similar subcellular compartment(s) that can be altered in the presence of P-gp inhibitors. Analysis of leukaemic cell lines and 50 AML patient samples showed that the level of P-gp mRNA or total P-gp protein correlated better with drug efflux than surface P-gp protein, suggesting that intracellular P-gp may contribute to MDR in AML. Therefore, the level of total P-gp protein or mRNA may be a better indicator of MDR than surface P-gp protein. In addition, we provide evidence for a novel mechanism of drug sequestration in K562 myeloid leukaemic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11301107     DOI: 10.1016/s0145-2126(00)00156-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

1.  Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells.

Authors:  Jingwei Zhang; Fang Zhou; Xiaolan Wu; Xiaoxuan Zhang; Yuancheng Chen; Beth S Zha; Fang Niu; Meng Lu; Gang Hao; Yuan Sun; Jianguo Sun; Ying Peng; Guangji Wang
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.

Authors:  Jing Jin; Hua Sun; Huailing Wei; Gengtao Liu
Journal:  Invest New Drugs       Date:  2007-04       Impact factor: 3.850

3.  The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug.

Authors:  Vivien Y Chen; Maria M Posada; Levi L Blazer; Tong Zhao; Gus R Rosania
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

4.  Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs.

Authors:  Oliver Thews; Birgit Gassner; Debra K Kelleher; Gerald Schwerdt; Michael Gekle
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

5.  Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.

Authors:  Jia-Yin Yang; Hua-You Luo; Qi-Yuan Lin; Zi-Ming Liu; Lu-Nan Yan; Ping Lin; Jie Zhang; Shong Lei
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

6.  Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance.

Authors:  Vivien Y Chen; Maria M Posada; Lili Zhao; Gus R Rosania
Journal:  Pharm Res       Date:  2007-08-01       Impact factor: 4.200

7.  P-Glycoprotein is not present in mitochondrial membranes.

Authors:  Jill K Paterson; Michael M Gottesman
Journal:  Exp Cell Res       Date:  2007-04-24       Impact factor: 3.905

8.  Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.

Authors:  Elon C Roti Roti; Scott K Leisman; David H Abbott; Sana M Salih
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

9.  Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells.

Authors:  Bao-An Chen; Yong-Yuan Dai; Xue-Mei Wang; Ren-Yun Zhang; Wen-Lin Xu; Hui-Ling Shen; Feng Gao; Qian Sun; Xiao-Jing Deng; Jia-Hua Ding; Chong Gao; Yun-Yu Sun; Jian Cheng; Jun Wang; Gang Zhao; Ning-Na Chen
Journal:  Int J Nanomedicine       Date:  2008

10.  LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.

Authors:  Benny Zhitomirsky; Hodaya Farber; Yehuda G Assaraf
Journal:  J Cell Mol Med       Date:  2018-01-26       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.